---
title: "Can-Fite submits Phase 2 Lowe syndrome trial protocol for Piclidenoson to Italy hospital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294682694.md"
description: "Can-Fite BioPharma submitted a Phase 2 trial protocol for Piclidenoson in treating Lowe syndrome to Bambino Gesù Children’s Hospital in Rome. The open-label, single-center study targets five adults over six months, aiming to support regulatory discussions and potential registration pathways based on positive results."
datetime: "2026-08-03T11:02:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294682694.md)
  - [en](https://longbridge.com/en/news/294682694.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294682694.md)
---

# Can-Fite submits Phase 2 Lowe syndrome trial protocol for Piclidenoson to Italy hospital

-   Can-Fite submitted a Phase 2 trial protocol for Piclidenoson in Lowe syndrome to Bambino Gesù Children’s Hospital in Rome for review. \* Open-label, single-center study targets 5 adults over six months, aiming to support regulatory discussions and a potential registration pathway on positive results. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030700PRIMZONEFULLFEED9802377) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)

## Related News & Research

- [Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer](https://longbridge.com/en/news/296095129.md)
- [Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance](https://longbridge.com/en/news/295654944.md)
- [Acea delays shareholder meeting to Sept. 28-29 from Sept. 7-8 on Rome Capital request](https://longbridge.com/en/news/296328692.md)
- [FC Porto agrees sale of 50% Rodrigo Mora economic rights to AS Roma for EUR 27 million](https://longbridge.com/en/news/296324307.md)
- [Abeona Therapeutics Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/295818848.md)